Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10day on/10day off prednisone regimen

Neuromuscular Disorders

Volumn 22, Issue 6, 2012, Pages 500-504

  ten Dam, K ^a   de Groot, I J M ^b   Noordam, C ^b   van Alfen, N ^a   Hendriks, J C M ^b   Sie, L T L ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alternating regimen; Duchenne muscular dystrophy; Growth retardation; Obesity; Prednisone

Indexed keywords

PREDNISONE;

ABSENCE OF SIDE EFFECTS; ARTICLE; BODY GROWTH; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CHILD CARE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INTERMITTENT THERAPY; DUCHENNE MUSCULAR DYSTROPHY; FOLLOW UP; HUMAN; MOBILIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; STEROID THERAPY;

BODY HEIGHT; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PREDNISONE; TREATMENT OUTCOME;

EID: 84860588580     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.01.005     Document Type: Article

References (23)

1. Emery A.E.H. Population frequencies of inherited neuromuscular diseases - A world survey. Neuromus Dis 1991, 1:19-29.
2. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989, 39:475-481.
3. Manzur A.Y., Kunzer T., Pike M., Swan A.V. Glucocorticoid corticosteroids for Duchenne muscular dystrophy (Review). Cochrane 2009, 3:1-73.
4. Moxley R.T., Pandya S., Ciafaloni E., Fox D.J., Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010, 25:1116-1129.
5. Balaban B., Matthews D.J., Clayton G.H., Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy. Am J Phys Med Rehab 2005, 84:843-850.
6. King W.M., Ruttencutter R., Nagaraja H.N., et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007, 68:1607-1613.
7. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle and Nerve 2007, 36:424-435.
8. Schara U., Mortier J., Mortier W. Long-term steroid therapy in Duchenne muscular dystrophy - Positive results versus side effects. J Clin Neuromus Dis 2001, 2:179-183.
9. Davidson Z.E., Truby H. A review of nutrition in Duchenne muscular dystrophy. J Human Nutri Dietetics: Off J British Dietetic Ass 2009, 22:383-393.
10. Allen D.B., Julius J.R., Breen T.J., Attie K.M. Treatment of glucocorticoid-induced growth suppression with growth hormone. Endocrinol Metab 1998, 83:2824-2829.
11. Nagel B.H., Mortier W., Elmlinger M., Wollmann H.A., Schmitt K., Ranke M.B. Short stature in Duchenne muscular dystrophy: a study of 34 patients. Actapaediatrica 1999, 88:62-65.
12. Eiholzer M., Bolthauser U., Frey E., Molinari D., Zachmann L. Short stature: a common feature in Duchenne muscular dystrophy. Eur J Pediatr 1988, 147:602-605.
13. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9:77-93.
14. de Groot I.J.M. Guideline on the use of corticosteroids in Duchenne muscular dystrophy from paediatric neurologists, neurologists and rehabilitation physicians [in Dutch]. Nederlandstijdschrift der Geneeskunde 2006, 150:2005-2006.
15. Dubowitz V., Kinali M., Main M., Mercuri E., Muntoni F. Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol 2002, 6:153-159.
16. Fredriks A.M., van Buuren S., Burgmeijer R.J., et al. Continuing positive secular growth change in The Netherlands 1955-1997. Pediatric Res 2000, 47(3):316-323.
17. Straathof C.S.M., Overweg-Plandsoen W.C.G., Burg van den G.J., et al. Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy. J Neurol 2009, 256:768-773.
18. Beenakker A.E.C., Fock J.M., Tol van M.J., et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 2005, 62:128-132.
19. Griffiths R., Edwards R.D. A new chart for weight control in Duchenne muscular dystrophy. Arch Disease Childhood 1988, 63:1256-1258.
20. Willig M.E.A., Carlier T.N., Legrand L. Nutritional assessments in Duchenne muscular dystrophy. Dev Med Child Neurol 1993, 35:1074-1082.
21. Mok E., Béghin L., Gachon P., et al. Estimating body composition in children with Duchenne muscular dystrophy: comparison of bioelectrical impedance analysis and skinfold-thickness measurement. Am J Clin Nutri 2006, 83:65-69.
22. Zanardi M.C., Tagliabue A., Orcesi S., Berardinelli A., Uggetti C., Pichiecchio A. Body composition and energy expenditure in Duchenne muscular dystrophy. Eur J Clin Nutri 2003, 57:273-278.
23. Pessolano F.A., Súarez A.A., Monteiro S.G., et al. Nutritional assessment of patients with neuromuscular diseases. Am J Phys Med Rehab/Ass Acad Physiatrists 2003, 82:182-185.